source
- ARPA-H launches $160 million THRIVE program to fund seven labs developing custom gene-editing therapies for rare diseasesARPA-H, the U.S. Advanced Research Projects Agency for Health, announced a new initiative called THRIVE with up to $160 million in funding. The program will support seven research teams over five…
- Prime Secures Arbitration Victory Over Beam, Paving Way for Clinical TrialsPrime, a biotech firm developing a gene‑therapy candidate, won an arbitration case against Beam Therapeutics. The ruling removes a legal hurdle and allows Prime to advance its program into clinical…